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Objective: Endoscopic ultrasonography is frequently used to locally stage 
esophageal cancer, but few studies exist to validate its accuracy for lymph 
node metastases. Our objective was to compare ndoscopic ultrasonogra- 
phy with video-assisted thoracoscopic and laparoscopic staging in evaluat- 
ing lymph node metastases in esophageal cancer. Methods: Twenty-six 
patients with potentially resectable sophageal cancer were identified by 
conventional imaging. Endoscopic ultrasonography was performed fol- 
lowed by laparoscopic and thoracoscopic staging, and locoregional staging 
was compared. Results: In eight patients endoscopic ultrasonography 
indicated NO disease, but laparoscopy and thoracoscopy documented Ni 
disease in six. In five of 26 (19%) obstruction prevented endoscopic 
ultrasonography; three had N1 by laparoscopy and thoracoscopy. Thirteen 
patients had N1 disease according to endoscopic ultrasonography, and 12 
of 13 (92%) had N1 disease by laparoscopy and thoracoscopy. The 
sensitivity and specificity of endoscopic ultrasonography for nodal evalua- 
tion were 65% and 66%, respectively. Sensitivity decreased to44% for lymph 
node metastases less than 1 cm. No instances of T4 disease were found by 
surgical staging when endoscopic ultrasonography indicated T3 disease. 
Endoscopic ultrasonography revealed no distant metastases in any patient, 
but in four of 26 (15%) laparoscopy identified liver metastases. Conclusions: 
The accuracy of endoscopic ultrasonography in the diagnosis of lymph node 
metastases in esophageal cancer was 65% and only 44% for lymph node 
metastases less than 1 cm diameter. Laparoscopy and thoracoscopy 
improved the accuracy of staging lymph node metastases in esophageal 
cancer and had the advantage of evaluating the thoracic and abdominal 
cavities for metastases. (J Thorac Cardiovasc Surg 1997;114:817-23) 
T he incidence of adenocarcinoma of the distal esophagus in the United States is increasing at an 
alarming rate. 1 The prognosis remains poor with an 
overall 5-year survival of 5% to 10%. Randomized 
trials of multimodality regimens have not been 
uniformly successful in improving survival over that 
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obtained with surgery alone. 2 One of the problems 
in the design of previous trials is that accurate 
pretreatment s aging has not been available. Con- 
ventional imaging modalities have been shown to be 
inaccurate in detecting limited metastatic disease in 
esophageal cancer compared with minimally inva- 
sive surgical staging by video-assisted thoracoscopy 
(VATS) and laparoscopy (LAP)) '  4 
Endoscopic ultrasonography (EUS) has been 
shown to accurately assess the depth of tumor 
penetration i to the esophageal wall (T status), but 
accuracy in assessing lymph node metastases has 
been questioned. 5-7 Another limitation of EUS is 
that in 20% to 38% of patients with esophageal 
cancer a high-grade malignant stricture precludes 
passage of an echoendoscope. Dilation and subse- 
quent EUS in this setting has a significant risk of 
perforation. 7 LAP/VATS has now been reported by 
several investigators as superior to conventional 
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Fig. 1. Right-sided view of port placements for LAP staging O f esophageal cancer. 
imaging modalities, but investigations comparing 
LAP/VATS and EUS for assessing lymph node 
metastases are limited. The objective of this study 
was to further investigate the accuracy of EUS and 
LAP/VATS in the detection of lymph node metas- 
tases in patients with esophageal cancer. 
Methods 
This was a prospective study of consecutive patients 
evaluated at the Pittsburgh Cancer Institute for poten- 
tially resectable sophageal cancer between July 1, 1995, 
and December 1, 1997. Resectability was determined by 
the Thoracic Surgery Service on the basis of conventional 
staging, which included computed tomography of the 
chest, abdomen, and head and bone scan. Patients with 
limited locoregional disease and no distant metastases 
were included. Patients with multiple enlarged lymph 
nodes with obliteration of normal tissue planes, consid- 
ered too extensive for complete resection, or those with 
distant metastases by conventional scanning were ex- 
cluded. EUS was performed on an outpatient basis. 
VATS/LAP staging was performed within 1 week of EUS. 
EUS. EUS was performed with the use of the linear 
electronic array 5/7.5 MHz ultrasonic endoscope (FG-32 
UA Echo Endoscope, Pentax Precision Instruments, 
Orangeburg, N.Y.). Patients were placed in the left lateral 
decubitus position. Meperidine (INN: pethidine) and 
midazolam were used to induce conscious edation and a 
topical anesthetic (Cetacaine) was used for local anesthe- 
sia of the or0pharynx. Th e echoendoscopic probe was 
then placed in the esophagus. The ultrasonic balloon was 
filled with water and 7.5 MHz frequency delivered. The 
entire length of the esophagus was evaluated sonographi- 
cally to assess lymph nodes in the periesophageal, celiac, 
and gastrohepatic regions. The tumor was also examined 
carefully to determine layer of origin, degree of esopha- 
geal wall invasion, and relationship to adjacent structures. 
Classification of tumor stage by EUS was based on the 
TNM staging classification. 8 Depth of tumor penetration 
(T status) was assigned by the same gastroenterologist 
(R.K.) who performed the EUS in all cases as follows: T1, 
wall thickening involving only mucosa nd submucosa; T2, 
tumor infiltration into muscularis propria, with a smooth 
outer margin; T3, tumor infiltration through muscularis 
propria, with an irregular outer margin; T4, tumor inva- 
sion of periesophageal tissue or adjacent organs. Lymph 
nodes were considered "positive" if they fulfilled one or 
more of the following criteria: distinct borders, rounded 
appearance, hypoechogenicity, and size larger than 1 cm. 
Minimally invasive staging (LAP/VATS). At the time 
of LAP and VATS, bronchoscopic and es0phagogas- 
toduoden0scopic examinations were also performed. In 
addition, all patients also had placement of a double- 
lumen Infuse-A-Port device (Strat0/Infusaid, Norwood, 
Mass.) for chemotherapy. 
LAP staging was performed first with the patient in the 
supine position. Five access ports were used. Two 10 mm 
ports were placed just to the right and left of the midline 
midway between the umbilicus and the xiphoid process. 
The port to the left of the midline was used for the 
telescope and the one to the right was used for dissecting 
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instruments. Two additional 5 mm ports were placed 
along the right costal margin, the lower right port being 
used for liver retractiOn and the upper for dissection (Fig. 
1). One additional 5 mm port was placed along the left 
costal margin for the assistant to provide countertraction. 
Initially a visual inspection was performed to rule out 
intraabdominal metastases. Next, the gastrohepatic l ga- 
ment was opened and lymph nodes were dissected. This 
dissection was extended into the periesophageal nd 
retroesophageal planes until either a diseased (positive) 
lymph node was detected by frozen section analysis or 
several benign lymph nodes were histologically verified. 
Once a positive intraabdominal node was verified by 
frozen section analysis we proceeded to VATS analysis. 
In most cases, a right-sided VATS approach was used, 
but if an indeterminate pulmonary nodule was present on 
the left side, a left-sided VATS approach was chosen. A 
double-lumen dotracheal tube was inserted in all cases. 
A total of four ports were placed for VATS staging (Fig. 
2). A 10 mm port was placed in the midaxillary line of the 
sixth intercostal space for the telescope. Two dissecting 5
mm ports were place at the fifth and eighth intercostal 
spaces posteriorly. An additional 5 mm port was placed 
anteriorly at the fifth intercostal space for the assistant to 
provide retraction of the lung medially. The hemithorax 
was inspected visually to rule out distant metastases. Next, 
the inferior pulmonary ligament was divided and the 
pleura overlying the lower one third of the esophagus was 
opened. Lymph nodes from the inferior pulmonary liga- 
ment and the subcarinal and periesophageal planes were 
dissected. The search was continued until either a positive 
node was verified by frozen section analysis or multiple 
lymph nodes from each of the areas just described were 
norma 1(negative). 
Statistics. The sensitivity, specificity, and accuracy of 
EUS was calculated by comparing the EUS nodal stage to 
the VATS/LAP histopathologic results. 
Results 
Twenty-six patients with potentially resectable 
esophageal cancer were identified during the study 
period. Adenocarcinoma of the gastroesophageal 
junction was present in 24 patients. Two patients 
had squamous cell Carcinoma of the esophagus 
located 25 to 30 cm from the incisors. EUS was 
possible in 21 patients. In five (19%), a high-grade 
malignant stricture prevented passage of the echo- 
endoscope. In three of these, LAP/VATS docu- 
mented N1 disease. In no cases did LAP/VATS 
identify a T4 lesion when T3 was diagnosed by EUS. 
LAP/VATS documented lymph node metastases 
in 21 of 26 patients (81%). Of the 21 patients in 
whom EUS was technically possible, N1 status was 
assigned in 12 (62%) but LAP/VATS results were 
positive in 18 (86%). In 13 patients, N1 disease was 
diagnosed by EUS and was confirmed by LAP/ 
VATS in 12 of the 13 (92%). In eight patients, EUS 
indicated stage N0 but LAP/VATS showed lymph 
Fig. 2. Typical port sites for right-sided VATS staging of 
esophageal cancer. 
node metastases in six. Compared with LAP/VATS 
for detecting lymph node metastases, EUS had a 
sensitivity of 65%, a specificity of 66%, and an 
accuracy of 65%. In all six cases in which EUS 
indicated stage NO and LAP/VATS stage N1, the 
lymph nodes were less than i cm in diameter (range 
0.2 to 1.0 cm). 
EUS did not detect metastatic disease in any case. 
In four of 26 cases, LAP/VATS identified small liver 
metastases. In three of these, the metastasis was in 
the left lobe of the liver and was less than 0.5 cm in 
diameter (Fig. 3). 
No complications were associated with EUS. Mi- 
nor complications after LAP and VATS are listed 
(Table I). The only major complication occurring 
after LAP was a small bowel obstruction on postop- 
erative day 3; this occurred as a result of a herniated 
loop of small bowel at a 10 mm port site. The hernia 
was reduced and repaired with no sequelae. The 
average operative time for LAP/VATS staging was 
4.2 hours (range 1 to 6 hours). The average length of 
hospital stay was 3.4 days (range 1 to 11 days). The 
operative time and hospital stay decreased uring 
the course of the study (Table II). 
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Fig. 3. Example of a 3 mm metastases to the left lobe of the liver missed by conventional staging and EUS 
and detected by LAP staging. 
Table I. Complications associated with minimally 
invasive staging procedures 
Table II. Operative time and hospital stay 
decreased with institutional experience 
Complication No. First 10 Last 10 
Major patients patients p Value 
Prolonged ileus 2 Operative time (hr) 4.2 _+ 0.5 3.6 + 0.3 p < 0.025 
Atelectasis 2 Length of stay (days) 3.4 _+ 0.8 1.8 _+ 0.3 p < 0.0i 
Urinary retention 2 
Port site infection 2 
Major 
Small bowel obstruction 1 accuracy in detecting lymph node metastases has 
been questioned. 5-7
Discussion 
Currently, no single noninvasive imaging modality 
or invasive procedure is an ideal staging method for 
esophageal cancer. An ideal modality should accu- 
rately assess for locoregional nd distant metastases 
and should limit costs. Computed tomography has 
recently been shown to be inaccurate in up to 40% 
of cases when followed by LAP and VATS. 3'4 
However, LAP and VATS are associated with minor 
morbidity and significant cost. Positron emission 
tomography has been shown by our group to dem- 
onstrate distant metastases in 20% of cases in which 
results of computed tomography and bone scanning 
were negative, but it shows only a 45% sensitivity for 
lymph node metastases that are less than 1 cm in 
diameter. 4 EUS offers the advantage of less cost 
than minimally invasive surgical staging, but its 
In the current study, we demonstrated that the 
accuracy of EUS was only 65% compared with 
minimally invasive surgical staging. The overall in- 
cidence of lymph node metastases when staged by 
LAP and VATS was 81%, which agrees with the 
results from pathologic analysis of radical esopha- 
gectomy studies reported elsewhere in similar pop- 
ulations of patients. TM This similarity suggests that 
our lymph node sampling at the time of minimally 
invasive surgical staging was adequate. The opera- 
tive times and associated cost for minimally invasive 
staging limits routine clinical application outside of 
protocol settings. However, these operative times 
included bronchoscopy, esophagoscopy, and place- 
ment of an Infuse-A-Port device. In addition, we 
also included the time required for placement of a 
double-lumen endotracheal tube and repositioning. 
The actual time for LAP and VATS was less than 1 
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hour for each procedure in our last 10 cases. The 
time required to perform minimally invasive surgical 
staging decreased significantly as experience in- 
creased (Table II). A prospective cost analysis was 
not performed, but average total charges for EUS 
are between $2,000 and $2,500 compared with 
$20,000 and $25,000 for total charges for a 1- to 
2-day hospital stay for VATS/LAP staging. In our 
series, 24 of 26 patients had an adenocarcinoma 
located at or near the gastroesophageal junction. 
The relevance of the findings of the current study to 
tumors at different locations or different cell types is 
not known. It is possible that thoracoscopic staging 
could be omitted in most cases of gastroesophageal 
junction adenocarcinomas inasmuch as we found 
only three cases of 26 in which LAP was negative for 
both lymph node metastases and distant metastases 
and VATS was positive for lymph node metastases. 
However, in cases of a negative LAP exploration of 
the abdomen, VATS should be performed to assure 
accurate staging. 
We are currently investigating the role of fine 
needle aspiration of lymph nodes at the time of 
EUS. If N1 disease can be histologically verified by 
EUS, a much less extensive surgical staging proce- 
dure would be required. In the setting of docu- 
mented lymph node metastases, presumably the 
only role for LAP or VATS would be to rule out 
distant metastases missed by conventional staging, 
although some investigators have shown that docu- 
menting the mere presence of N1 disease is not 
adequate to accurately assess prognosis. For exam- 
ple, the number of lymph nodes involved 9-11 and 
their location above and below the diaphragm 12 may 
be important prognostic factors. For adenocarcino- 
mas of the gastroesophageal junction, we found no 
cases of intrathoracic distant metastases missed by 
conventional scanning but did identify four cases of 
occult liver metastases. Confirmation by larger pro- 
spective studies will be required to determine the 
role of VATS in this setting. 
In conclusion, current criteria for defining lymph 
node metastases by EUS in the setting of esophageal 
cancer are inaccurate. We use EUS as a complimen- 
tary diagnostic procedure that accurately assesses 
tumor depth of penetration and in some cases allows 
tissue diagnosis by fine needle aspiration. For accu- 
rate assessment of lymph node metastases and to 
rule out occult metastases in the patient with esoph- 
ageal cancer, histologic verification is required in 
most cases by minimally invasive surgical staging. 
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Discuss ion 
Dr. Thomas W. Rice (Cleveland, Ohio). Esophageal 
carcinoma is no longer a single entity with a uniformly 
dismal prognosis. Early-stage cancers can be detected 
because of the epidemic of adenoearcinoma in middle- 
aged and elderly white men, a growing appreciation ofthe 
malignant potential of Barrett's esophagus, and the in- 
creasing use of surveillance ndoscopy. The spectrum of 
the disease is now obvious. In the selection of surgical 
candidates, pretreatment s aging is crucial and allows 
modification of therapy for locally advanced tumors. 
EUS is a superb staging tool. We have used endosonog- 
raphy in staging the disease of our patients for the past 
decade. The goal of clinical staging is to identify T3 and 
N1 disease, because patients with this stage of disease 
have a poor surgical survival. Esophageal endosonography 
is the best clinical instrument for the evaluation of T stage. 
If T3 or T4 disease is found, the patient has locally 
advanced isease, and identification of N1 disease is an 
added luxury but not essential for treatment. 
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The confirmation of N1 disease becomes critical when it 
affects treatment and survival. An accuracy of 80% or 
greater in the determination of regional lymph node 
status is reported by most centers with an extensive 
experience with EUS. 
The following practical lessons have improved the 
endosonographic detection of N1 disease in our practice: 
(1) The instrument you chose, a sector scanner, is better 
suited for diagnosis than staging. (2) A dedicated en- 
dosonographer should perform all studies with pathologic 
verification of clinical staging when possible. It takes at 
least 50 to 100 examinations to become competent in 
technique and interpretation of EUS. A malignant stric- 
ture, which you found, as we did, precludes EUS in 20% 
of patients, is the most accurate predictor of advanced 
disease. Ninety percent of patients in whom the scope 
cannot be advanced will have stage I l I  or IV disease. 
Another accurate predictor of N1 disease is the proximity 
of the regional node to the tumor. The relationship of T to 
N1 is helpful because 80% of patients with T3 and T4 
disease have N1 disease. The comparison of the echo 
characteristics of the tumor and the node is most useful, 
and the standard criteria of a malignant node, size, shape, 
border, and internal echo patterns augment this list. 
Finally, in the assessment of the indeterminate node, 
EUS-directed fine needle aspiration further refines clini- 
cal staging by adding tissue sampling to these EUS 
findings. 
In our patients EUS is an outpatient procedure that 
adds 10 to 20 minutes to endoscopic examination of the 
upper gastrointestinal tract, and the patient is charged 
$1000. This must be compared with the combination of 
LAP and VATS, which requires hospitalization, a general 
anesthetic, a 4- to 5-hour operation, and an average stay of 
3 days, with the potential of an l l -day stay. Some of these 
statistics are equivalent to those of esophagectomy. 
This procedure also potentially violates the tumor and 
requires dissection of the vascular supply of the stomach. 
The effects on future resection and reconstruction are 
unknown. 
We rely on EUS for clinical staging and use VATS and 
LAP as adjuncts to answer specific questions not ad- 
dressed by noninvasive staging techniques. 
Dr. Luketich. Thank you, Dr. Rice, for your comments. 
As I mentioned, we do share the concern over cost. One 
of the biggest advantages of LAP and VATS is that it 
allows the physician to evaluate for distant metastatic 
disease, which we found in between 15% and 20% of 
cases, which avoids the major morbidity and cost of 
esophagectomy. 
Regarding the accuracy of EUS, for T2 NO cases, when 
results of EUS have been negative we have found positive 
lymph nodes in six of our eight cases. However, I think 
that you are right for T3, bulky tumors. Most of those 
patients are going to have N1 disease, and in some studies 
this has been confirmed by surgical follow-up. However, 
EUS findings have not been well documented by lymph 
node mapping in most series but simply confirmed as "N," 
after surgical resection. I know you would agree that I 
could arbitrarily stage most bulky T3 tumors as N1 and I 
would probably be right in about 80% of cases. I am not 
sure that most physicians can use EUS to specifically 
identify metastatic nodes; they may just be seeing nodes 
and calling them positive. Lymph node mapping and 
further studies need to be done to determine whether 
EUS can identify the extent and location of metastatic 
lymph nodes that may be important prognostically. 
We are ready to start up a new trial working with our 
endoscopist. We are doing intraoperative EUS: When a 
lymph node appears positive by EUS, it is injected with 
methylene blue and surgically dissected to more closely 
evaluate EUS and its accuracy. Clearly from a cost 
standpoint, EUS is attractive and it is unparalleled in its 
ability to assess T status. Our goal is to more closely 
evaluate EUS accuracy for lymph node metastasis and not 
to exclude EUS from our practice. 
Dr. Nasser K. Aitorki (New York, N.Y.). You have made 
a powerful case against EUS, at least for detection of 
nodal metastases. I am not sure your case is quite as 
persuasive for staging of minimally invasive disease. We 
have stopped using EUS to evaluate nodal metastases. We 
use it primarily to evaluate the T status. We examined the 
correlation between T status and what we found at 
operation. If the lesion is stage T2, the prevalence of 
positive nodes is 50%. If the lesion is stage T3, whether it 
is constricting or not, the prevalence of positive nodes 
goes up to 80%. Therefore, if the lesion is not stage T1, we 
consider that the probability of nodal metastases i  very 
high. Have you made any correlation between the T status 
and the prevalence of nodal disease? 
Dr. Luketich. We made a very similar observation. Our 
concern is, of course, looking at those lesions that are 
stage NO by EUS, which have a high likelihood or at least 
a potential for periesophageal lymph node metastasis and 
might be stratified to pretreatment chemotherapy. Inas- 
much as neoadjuvant therapy has not been proven in most 
studies to add any benefit o surgical resection, we think it 
is important o definitively stage the disease before mul- 
timodality treatment protocols. For bulky T3 tumors, you 
can make an argument for going right ahead with your 
treatment strategies. However, because of our disappoint- 
ment over recent multimodality results, if minimally inva- 
sive staging changes the stage of T3 or T2 tumors or 
identifies radiographically occult metastases in even 20% 
of patients, this may help us to more closely evaluate 
response rates, downstaging, and the impact of multimo- 
dality therapy on subsets of patients. As EUS develops 
in terms of the fine-needle aspiration capability, histo- 
logic verification would allow accurate staging before 
randomizing patients to different treatment regimens. 
This still does not address radiographically occult metas- 
tases, which have been reported in about 20% of series 
that include minimally invasive surgical staging. 
Dr. Mark J. Krasna (Baltimore, Md.). I think the reason 
your operating room times were twice as long as mine is 
that you are very meticulous and are getting more lymph 
nodes. This discussion on lymph node spread is probably 
very good. Whether EUS, VATS, LAP, or en bloc esoph- 
agectomy with two or three fields is used, I think finally 
people are getting the message, that we can prognosticate 
esophageal cancer by simply proving whether or not 
lymph nodes are involved. That is a lesson that was taught 
to me by Dr. Ellis years ago, and we have been proving it 
true ever since. Unfortunately, as you said, this matter will 
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not be clear in time for the next intergroup trial, and that 
trial probably will lump together all patients and all stages 
of esophageal cancer; however, ideally it will at least 
stratify up front by the different stages. I do think, though, 
that in the future we will be able to tell, whether by EUS 
or VATS or LAP, whether the lymph nodes are involved 
or not, and make the decision on that basis for a radical 
resection versus perhaps multimodality herapy. 
In your abstract, you listed a number of patients who 
had positive lymph nodes overall. Can you break down 
how many of those positive nodes were abdominal lymph 
nodes versus thoracic lymph nodes? Also, do you know 
how many patients eventually went on to resection? 
Dr. Luketich. Thank you, Dr. Krasna. Of the 21 patients 
who could undergo EUS, approximately 40% had positive 
lymph nodes according to LAP and VATS, another 40% 
had LAP-positive nodes only, with VATS results being 
negative, and only a small number in our series, 20%, had 
LAP-negative results with VATS then identifying a small 
metastatic periesophageal lymph node. 
Dr. Malcolm M. DeCamp, Jr. (Boston, Mass.). As 
someone who is doing this myself, I am always perplexed 
at when to decide that the diagnosis i  "negative." Could 
you comment on those patients with small nodes, those 
patients in whom your suspicion is low clinically? How 
much dissection you do and how many nodes do you 
sample before you decide that the stage is NO and quit? 
Dr. Luketich. I think that is why the range of time is 
variable. When we go into the abdomen and we find a 
gastrohepatic node that is easily dissectable, it is a 30- 
minute procedure. However, when that gastrohepatic 
node is histologically negative, we continue to dissect out 
nodes. Early on in our experience we were not meticulous 
enough, and even minor bleeding makes lymph node 
identification difficult. A bloodless field is essential for 
retroesophageal and celiac nodal identification. That is a 
challenge laparoscopically and takes more time. The more 
cases I do, the more reluctant I am to leave the abdomen 
with a gastroesophageal junction tumor that is at the T3 
level and call it NO. I Cannot specify a time. However, we 
certainly dissect nodes at the gastrohepatic ligament as 
well as periesophageal, retroesophageal, nd celiac nodes 
before we will decide that it is a laparosc0pically negative 
case. 
At VATS, we mobilize the distal esophagus and take 
out periesophageal nodes. I have personally found that 
to be most rewarding in terms of dissection. Black 
anthracotic nodes are not of much help, because they 
are easy to get out but they often do not have the 
metastatic deposit. You can take out the subcarinal nd 
the infrapulmonary ligament lymph nodes because they 
are easy to resect, but they are usually negative in our 
experience. For the gastroesophageal junction tumors, 
to get a positive node in the chest it is necessary to 
resect a periesophageal node, and that requires opening 
the pleura. As Dr. Rice mentioned, opening the pleura 
may be disadvantageous. In our more recent patients; 
we have tried to stay linear with the pleural opening and 
close it with an endoscopic suture. 
We have found that after minimally invasive staging and 
multimodality herapy, resection at a later date is a more 
difficult dissection. 
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